These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38543560)

  • 1. Comparison of Neutralizing Activity between Vaccinated and Unvaccinated Hospitalized COVID-19 Patients Infected with Delta, Omicron BA.1, or Omicron BA.2 Variant.
    Kim KJ; Park SJ; Yun SG; Kim SW; Nam MH; Shin EK; Chang EA; Park DW; Lee CK; Yoon YK; Cho Y
    Microorganisms; 2024 Mar; 12(3):. PubMed ID: 38543560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral Response Kinetics and Cross-Immunity in Hospitalized Patients with SARS-CoV-2 WT, Delta, or Omicron Infections: A Comparison between Vaccinated and Unvaccinated Cohorts.
    Kang H; Lee J; Jung J; Oh EJ
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron infection enhances Delta antibody immunity in vaccinated persons.
    Khan K; Karim F; Cele S; Reedoy K; San JE; Lustig G; Tegally H; Rosenberg Y; Bernstein M; Jule Z; Ganga Y; Ngcobo N; Mazibuko M; Mthabela N; Mhlane Z; Mbatha N; Miya Y; Giandhari J; Ramphal Y; Naidoo T; Sivro A; Samsunder N; Kharsany ABM; Amoako D; Bhiman JN; Manickchund N; Abdool Karim Q; Magula N; Abdool Karim SS; Gray G; Hanekom W; von Gottberg A; ; Milo R; Gosnell BI; Lessells RJ; Moore PL; de Oliveira T; Moosa MS; Sigal A
    Nature; 2022 Jul; 607(7918):356-359. PubMed ID: 35523247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections.
    Brazer N; Morris MK; Servellita V; Anglin K; Saldhi P; Garcia-Knight M; Bethancourt S; Sotomayor-Gonzalez A; Wang B; Foresythe A; Nguyen J; Gliwa AS; Pineda-Ramirez J; Sanchez RD; Zhang Y; Ott M; Wadford DA; Andino R; Kelly JD; Hanson C; Chiu CY
    J Infect Dis; 2022 Nov; 226(10):1688-1698. PubMed ID: 36134603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
    Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
    J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
    Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
    Richardson SI; Madzorera VS; Spencer H; Manamela NP; van der Mescht MA; Lambson BE; Oosthuysen B; Ayres F; Makhado Z; Moyo-Gwete T; Mzindle N; Motlou T; Strydom A; Mendes A; Tegally H; de Beer Z; Roma de Villiers T; Bodenstein A; van den Berg G; Venter M; de Oliviera T; Ueckermann V; Rossouw TM; Boswell MT; Moore PL
    Cell Host Microbe; 2022 Jun; 30(6):880-886.e4. PubMed ID: 35436444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
    Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Jan; ():. PubMed ID: 35118480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.
    Singh J; Anantharaj A; Panwar A; Rani C; Bhardwaj M; Kumar P; Chattopadhyay P; Devi P; Maurya R; Mishra P; Pandey AK; Pandey R; Medigeshi GR
    PLoS Pathog; 2023 Feb; 19(2):e1011196. PubMed ID: 36827451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.